{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094896","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-08-12T20:16:29+00:00","discovered_at":"2026-08-12T20:18:00.255600+00:00","generated_at":"2026-08-12T20:18:37.784136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Armata posts Q2 net income $74.1M on non-cash gain; AP-SA02 Phase 3 on track","bullets":["Q2 2026 net income $74.1M vs net loss $16.3M in 2025; basic EPS $2.02, diluted loss $0.27.","Operating loss $10.3M vs $6.8M; R&D $7.6M, G&A $5.2M; grant revenue $2.5M.","Received $2.5M additional DoW funding, total $28.7M; cash $24.0M vs $8.7M at end-2025.","FDA granted Fast Track designation for AP-SA02; Phase 3 protocol submitted; Agreed iPSP obtained.","Promoted David House to CFO; appointed Daniel B. Gilmer, Ph.D. to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094896","json":"https://secwatch.observer/filing/0001104659-26-094896.json","markdown":"https://secwatch.observer/filing/0001104659-26-094896.md","text":"https://secwatch.observer/filing/0001104659-26-094896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/0001104659-26-094896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:18:37.784136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}